Abstract:Toll-like receptor 4 (TLR4) is a toll-like receptor (TLR) family protein that organizes an innate immune response that distinguishes nonself and endogenous danger signals. Specifically, TLR4 recognizes lipopolysaccharide (LPS) from the cell wall of Gram-negative bacteria, as well as endogenous signals such as HSP60, HSP70, and fibrinogen. Agonism of the receptor is dependent upon a homodimeric TLR4 signaling complex that ACHTUNGTRENNUNGincludes myeloid differentiation factor 2 (MD2). The assembly of the TLR4–MD2 complex initiates a MyD88-dependent signaling cascade, which relocates nuclear factor-kB (NF-kB) from the cytoplasm to the nucleus. Transcription by the NF-kB promoter directs the production of a number of proinflammatory cytokines including TNFa, IL-1b, IL-6, and IFN-g. Recent evidence suggests that TLR4-mediated elevations in the expression of these cytokines in glia cells and astrocytes in the central nervous system (CNS) initiate and propagate several debilitating disease states such as chronic pain and sepsis. The lack of good clinical treatments for chronic pain has made its effectors, including TLR4, popular targets for new therapeutics. Chronic pain occurs in epidemic proportions worldwide. The disease typically arises from two types of injuries : 1) tissue injuries that lead to inflammatory pain, and 2) nerve injuries that lead to neuropathic pain. Microglia in the CNS recognize a variety of signals associated with inflammatory or nerve injury and subsequently release a variety of inflammatory mediators in response, including TNFa, IL-1b, IL-6, PGE-2, COX-2, and ATP. The release of these molecules stimulates other glia to respond in a proinflammatory manner, and also results in neuronal actions. Stimulation of nociceptive pain neurons by glial inflammatory mediators leads to hypersensitivity and enhanced pain states. This centrally mediated pathological pain causes exaggerated pain sensitivity in healthy and undamaged tissues. The hypersensitive state leads to intense and exaggerated pain being sensed from both painful (hyperalgesia) and/or nonpainful stimuli (allodynia). 8] Previous research has indicated that TLR4 plays a major role in the development of chronic pain. TLR4 is now well documented to become activated by so-called “endogenous danger signals”. These are substances released by stressed or damaged cells (such as the HMGB-1, and HSP proteins, etc.) that signal distress of host cells through TLR4 signaling, which leads to glial release of proinflammatory mediators. In fact, TLR4-knockout mice that have undergone nerve injury do not develop allodynia and show reduced glial activation with lower levels of pain-related mediators. Moreover, hypersensitivity can be attenuated in chronic pain rats by using a TLR4 antisense oligonucleotide. TLR4 signaling is dependent upon the formation of a homodimer, which is mediated by the accessory protein MD2. 14] Specific point mutations to MD2 (for example, Cys95Tyr), which prevent its association with TLR4, significantly diminishes TLR4 signaling. TLR4-based peptides or TLR4-MD2 fusion proteins can also attenuate signaling by competing for MD2 or LPS respectively . 17] Given the wide array of agonists that TLR4 recognizes, it is not clear whether a peptide that targets TLR4 directly would agonize or antagonize the receptor. The recently reported high-resolution X-ray crystal structure of the murine TLR4–MD2 complex revealed several molecular recognition sites on the TLR4–MD2 interface that could serve as potential targets for a peptide. A charged patch spanning from Asp99 to Glu111 (critical charged residues are underlined in Table 1) of MD2 was projected to be critical to the nanomolar binding affinity of MD2 and TLR4. These charged residues are projected by a short a helix (Ser103–Lys109) and a random-coil protruding loop (Cys95–Tyr102) that is constrained by a disulfide bridge between Cys95 and Cys105. Herein, we employed a chemical biology approach by utilizing the minimal TLR4binding region of MD2 to block the TLR4–MD2 association. The in silico, in vitro, and whole-cell data demonstrated for the

Therapeutic Targeting of TLR4 for Inflammation, Infection, and Cancer: A Perspective for Disaccharide Lipid A Mimetics

Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics

Exploring Species-Specificity in TLR4/MD-2 Inhibition with Amphiphilic Lipid A Mimicking Glycolipids

A Peptide Antagonist of the TLR4-MD2 Interaction.

Nonreducing Sugar Scaffold Enables the Development of Immunomodulatory TLR4‐specific LPS Mimetics with Picomolar Potency

Small-Molecule Modulators of Toll-like Receptors

Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.

A Peptide Antagonist of the TLR 4 – MD 2 Interaction

Recent progress in the development of Toll-like receptor (TLR) antagonists

Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory Response.

Establishing the Structural Rules for Ligand Recognition, Signaling and Assembly in Innate Immune Receptors

Targeting Toll-Like Receptors With Small Molecule Agents

Structure‐Based Design and Synthesis of Lipid A Derivatives to Modulate Cytokine Responses

From Molecular Mechanisms to Clinical Applications

The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases

TLR Signaling Pathways: Opportunities for Activation and Blockade in Pursuit of Therapy

Synthesis and immunological evaluation of a low molecular weight saccharide with TLR-4 agonist activity

TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS

Full-Atom Model of the Agonist LPS-Bound Toll-like Receptor 4 Dimer in a Membrane Environment

Comparative Analysis of Sulfated and Sulfonated Disaccharide Analogs as TLR4 Modulators and Heparanase Inhibitors